Demographic Barriers for Genetic Testing in High-Risk Breast Cancer Patients in the Northern Michigan Area

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Apr 12

PMID 35411261

Authors

Danielle Hebert

Felipe Pacheco

Lisa WintonLi

Asma Taj

Affiliations

Soon will be listed here.

Abstract

Introduction: The National Comprehensive Cancer Network (NCCN) has outlined guidelines for criteria regarding genetic testing for high-penetrance breast and/or ovarian cancer susceptibility genes. Due to the lack of availability of genetic counseling services in Northern Michigan prior to COVID-19, the utilization of genetic testing falls well below recommended guidelines.

Methods: Patients diagnosed with breast cancer in 2019 were randomly selected from Ascension Michigan's Northern Ministries Tumor Registry. A retrospective chart review was conducted. For patients who met NCCN criteria, their medical records were used to determine if genetic testing was recommended and if genetic testing was completed. Univariate (Crosstabs and t-tests) and multivariate tests with logistic regression were used to identify significant associations between the variables of interest.

Results: One hundred and two (102) patient charts were reviewed in this group; 55 (52.4%) were eligible by the NCCN guidelines for genetic testing. From this eligible subset of patients, only 29 were offered genetic testing, and only 21 were tested. The mean age of the patients offered genetic counseling was 56.2 years compared and 67.6 years in the group not offered counseling (p < 0.001). The patient's insurance type was an independent factor for obtaining genetic testing, specifically, the subgroup who had Medicare (OR = 0.73, CI = 0.01-0.54; p = 0.02). Patients insured through Medicare were less likely to obtain genetic testing after referral to a genetic counselor (p = 0.01).

Conclusion: Genetic counseling for high-risk breast cancer patients is below average in Northern Michigan, likely related to lack of physician referral, poor availability of counseling services, low socioeconomic status as well as a lower level of concern in older ages.

References

Litton J, Burstein H, Turner N . Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019; 39:e1-e7. DOI: 10.1200/EDBK_237715. View

Katz S, Ward K, Hamilton A, McLeod M, Wallner L, Morrow M . Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol. 2018; 36(12):1218-1224. PMC: 5908222. DOI: 10.1200/JCO.2017.76.2369. View

Delikurt T, Williamson G, Anastasiadou V, Skirton H . A systematic review of factors that act as barriers to patient referral to genetic services. Eur J Hum Genet. 2014; 23(6):739-45. PMC: 4795051. DOI: 10.1038/ejhg.2014.180. View

Daly M, Pilarski R, Yurgelun M, Berry M, Buys S, Dickson P . NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw. 2020; 18(4):380-391. DOI: 10.6004/jnccn.2020.0017. View

DeSantis C, Ma J, Gaudet M, Newman L, Miller K, Sauer A . Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6):438-451. DOI: 10.3322/caac.21583. View

Cohen S, Bradbury A, Henderson V, Hoskins K, Bednar E, Arun B . Genetic Counseling and Testing in a Community Setting: Quality, Access, and Efficiency. Am Soc Clin Oncol Educ Book. 2019; 39:e34-e44. DOI: 10.1200/EDBK_238937. View

Jones T, McCarthy A, Kim Y, Armstrong K . Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study. Cancer Med. 2017; 6(7):1787-1798. PMC: 5504315. DOI: 10.1002/cam4.1120. View

Couch F, Shimelis H, Hu C, Hart S, Polley E, Na J . Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017; 3(9):1190-1196. PMC: 5599323. DOI: 10.1001/jamaoncol.2017.0424. View

Kne A, Zierhut H, Baldinger S, Swenson K, Mink P, McCarthy Veach P . Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter. J Genet Couns. 2016; 26(4):697-715. DOI: 10.1007/s10897-016-0040-0. View

10.

Kurian A, Griffith K, Hamilton A, Ward K, Morrow M, Katz S . Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer . JAMA. 2017; 317(5):531-534. PMC: 5530866. DOI: 10.1001/jama.2016.16918. View

11.

Uhlmann W, McKeon A, Wang C . Genetic counseling, virtual visits, and equity in the era of COVID-19 and beyond. J Genet Couns. 2021; 30(4):1038-1045. PMC: 8426877. DOI: 10.1002/jgc4.1469. View

12.

Bayraktar S, Arun B . BRCA mutation genetic testing implications in the United States. Breast. 2016; 31:224-232. DOI: 10.1016/j.breast.2016.11.021. View

13.

Kinney A, Butler K, Schwartz M, Mandelblatt J, Boucher K, Pappas L . Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial. J Natl Cancer Inst. 2014; 106(12). PMC: 4334799. DOI: 10.1093/jnci/dju328. View

14.

Plichta J, Sebastian M, Smith L, Menendez C, Johnson A, Bays S . Germline Genetic Testing: What the Breast Surgeon Needs to Know. Ann Surg Oncol. 2019; 26(7):2184-2190. DOI: 10.1245/s10434-019-07341-8. View

15.

Copur M . Universal Genetic Testing for All Breast Cancer Patients. Oncology (Williston Park). 2019; 33(8). View

16.

Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K . Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers. Proc (Bayl Univ Med Cent). 2019; 32(3):340-344. PMC: 6650213. DOI: 10.1080/08998280.2019.1612702. View